On Jun 29, 2018 CymaBay Therapeutics (NASDAQ:CBAY) with $20 Target Analyzed by Raymond James.

June 29, 2018 - By Robert Case

What Price Target Has Raymond James Given CymaBay Therapeutics (NASDAQ:CBAY)

Raymond James’s Expert analysts have $20 price target which indicates upside potential of 48.81 % on CymaBay Therapeutics (NASDAQ:CBAY). Raymond James also has initiated coverage of CBAY stock on Thursday morning.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

A total of 9 analysts rate CymaBay Therapeutics (NASDAQ:CBAY) as follows: 9 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CBAY) has 17 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Wednesday, January 31 the firm has “Buy” rating given by Piper Jaffray. In Wednesday, March 28 report Leerink Swann maintained it with “Buy” rating and $1600 target. On Wednesday, April 11 Leerink Swann maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) with “Buy” rating. In Wednesday, March 21 report Oppenheimer maintained the stock with “Buy” rating. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, January 24. On Tuesday, June 26 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald. The stock rating was maintained by Oppenheimer with “Buy” on Wednesday, January 10. On Thursday, January 25 the firm has “Buy” rating by Roth Capital given. On Monday, April 16 the company was maintained by Roth Capital. On Wednesday, March 28 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright.

The stock increased 0.45% or $0.06 during the last trading session, hitting $13.44.Currently CymaBay Therapeutics, Inc. is uptrending after 171.12% change in last June 29, 2017. CBAY has 163,460 shares volume. CBAY outperformed by 158.55% the S&P 500.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY)’s quarterly earnings will be published on August, 9., Zacks reports. Analysts expect change of 22.58 % or $0.07 from previous year’s $-0.31 EPS compared to current’s $-0.24 EPS. Wall Street now forecasts -25.00 % EPS growth despite CymaBay Therapeutics, Inc. previous quarter’s EPS of $-0.32.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.The company has $789.85 million market cap. The Company’s lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.Currently it has negative earnings. The firm also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications.

For more CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news announced recently go to: Seekingalpha.com, Seekingalpha.com, Streetinsider.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Key events next week – healthcare” announced on June 21, 2018, “Reader Inquiry: What’s The Updated Outlook For CymaBay Therapeutics?” on June 03, 2018, “SunTrust Robinson Humphrey Remains Bullish on CymaBay Therapeutics (CBAY) Following Analyst & Investor Day” with a publish date: June 28, 2018, “CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes” and the last “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” with publication date: June 12, 2018.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.